Hematology

FDA approves first treatment for children and adolescents with PNH

The U.S. Food and Drug Administration has approved the expanded use of ravulizumab-cwvz (Ultomiris; Alexion Pharmaceuticals) to include children >1 month of age and adolescents with paroxysmal nocturnal hemoglobinuria (PNH), according to a press release. This is the first FDA-approved medicine with children and adolescents with PNH. Rvulizumab-cwvz was approved...